Availability of effective protein therapeutics has been held back by the high cost and lengthy process of traditional drug development. Our Better DNA™ approach can substantially reduce the discovery/development cycle for targeted protein biologics, increasing access to new and improved therapies.
End-to-end Human Antibody Development and Production
Fully human antibodies have reduced probability of evoking neutralizing antibodies or allergic reactions compared with animal-derived, chimeric, or “humanized” antibodies
We are seeking partners to collaborate on the development of therapeutic product candidates in specialties such as:
To discuss collaboration opportunities, click the link below to contact us.